FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3027274368> ?p ?o ?g. }

• W3027274368 abstract "Abstract Background An increasing body of evidence suggests that immune dysregulation is involved in the pathophysiology of psychotic disorders. Some, but not all, anti-inflammatory drugs have shown positive effects on symptom severity. Given the need for new treatment options in psychosis, anti-inflammatory medication should be explored as a potential treatment to improve outcome. Being a potent glucocorticosteroid that adequately passes through the blood-brain barrier, prednisolone qualifies as a potential candidate. This proof-of-concept study aims to explore the effect of prednisolone, compared to placebo, on symptom severity in patients with a psychotic disorder who are on a stable dose of antipsychotic medication. Methods The study was conducted from July 2015 until April 2019 in four centers in the Netherlands and Belgium. Patients with a psychotic disorder were randomized, double blind, 1:1 to prednisolone or placebo in addition to their antipsychotic treatment. Patients randomized to prednisolone started with 40 mg/day, tapered down to zero in six weeks. Several procedures were implemented to ensure patient safety during prednisolone exposure (e.g. regular safety labs). The primary objective was to compare change in symptom severity, measured through the Positive and Negative Syndrome Scale (PANSS), in patients treated with prednisolone versus placebo, in additional to a stable antipsychotic regimen. To this end, a mixed model repeated measures ANOVA was applied. Results 42 participants were randomized, equally divided across the treatment arms. The six week treatment period was completed by 20 patients randomized to placebo and 19 patients randomized to prednisolone. There were no baseline differences in demographics, symptom severity, depression or global functioning between the treatment groups. There was no difference in symptom improvement between patients treated with prednisolone compared to placebo at the end of the six week treatment period (p=.304). Global functioning and depression were not significantly different between treatment arms end of treatment. No Serious Adverse Events (SAEs) occurred during the treatment phase. Discussion The results of this proof-of-concept study do not support the immune hypothesis of psychosis: there was no difference in symptom improvement after a six week treatment with prednisolone compared to placebo, in addition to a stable regimen of antipsychotics. The small sample size is the main limitation of this trial. Even though prednisolone did not show to be a potential candidate for augmentation therapy in psychosis, it is of interest to note that patients did not deteriorate when using prednisolone nor were there more SAE’s in the active treatment arm. This argues against the general safety concerns for prescribing prednisolone in patients with psychosis for the treatment of immune disorder, although additional research is needed." @default.
• W3027274368 created "2020-05-29" @default.
• W3027274368 creator A5024072640 @default.
• W3027274368 creator A5031613969 @default.
• W3027274368 creator A5035580474 @default.
• W3027274368 creator A5087058519 @default.
• W3027274368 date "2020-04-01" @default.
• W3027274368 modified "2023-10-16" @default.
• W3027274368 title "T43. PREDNISOLONE VERSUS PLACEBO AS AUGMENTATION THERAPY IN PSYCHOTIC DISORDERS" @default.
• W3027274368 doi "https://doi.org/10.1093/schbul/sbaa029.603" @default.
• W3027274368 hasPublicationYear "2020" @default.
• W3027274368 type Work @default.
• W3027274368 sameAs 3027274368 @default.
• W3027274368 citedByCount "0" @default.
• W3027274368 crossrefType "journal-article" @default.
• W3027274368 hasAuthorship W3027274368A5024072640 @default.
• W3027274368 hasAuthorship W3027274368A5031613969 @default.
• W3027274368 hasAuthorship W3027274368A5035580474 @default.
• W3027274368 hasAuthorship W3027274368A5087058519 @default.
• W3027274368 hasBestOaLocation W30272743681 @default.
• W3027274368 hasConcept C118552586 @default.
• W3027274368 hasConcept C126322002 @default.
• W3027274368 hasConcept C142724271 @default.
• W3027274368 hasConcept C15744967 @default.
• W3027274368 hasConcept C168563851 @default.
• W3027274368 hasConcept C204787440 @default.
• W3027274368 hasConcept C27081682 @default.
• W3027274368 hasConcept C2776412080 @default.
• W3027274368 hasConcept C2776715498 @default.
• W3027274368 hasConcept C2779727114 @default.
• W3027274368 hasConcept C2780135775 @default.
• W3027274368 hasConcept C2780494398 @default.
• W3027274368 hasConcept C2781413609 @default.
• W3027274368 hasConcept C71924100 @default.
• W3027274368 hasConceptScore W3027274368C118552586 @default.
• W3027274368 hasConceptScore W3027274368C126322002 @default.
• W3027274368 hasConceptScore W3027274368C142724271 @default.
• W3027274368 hasConceptScore W3027274368C15744967 @default.
• W3027274368 hasConceptScore W3027274368C168563851 @default.
• W3027274368 hasConceptScore W3027274368C204787440 @default.
• W3027274368 hasConceptScore W3027274368C27081682 @default.
• W3027274368 hasConceptScore W3027274368C2776412080 @default.
• W3027274368 hasConceptScore W3027274368C2776715498 @default.
• W3027274368 hasConceptScore W3027274368C2779727114 @default.
• W3027274368 hasConceptScore W3027274368C2780135775 @default.
• W3027274368 hasConceptScore W3027274368C2780494398 @default.
• W3027274368 hasConceptScore W3027274368C2781413609 @default.
• W3027274368 hasConceptScore W3027274368C71924100 @default.
• W3027274368 hasLocation W30272743681 @default.
• W3027274368 hasLocation W30272743682 @default.
• W3027274368 hasOpenAccess W3027274368 @default.
• W3027274368 hasPrimaryLocation W30272743681 @default.
• W3027274368 hasRelatedWork W11659520 @default.
• W3027274368 hasRelatedWork W12933269 @default.
• W3027274368 hasRelatedWork W4671169 @default.
• W3027274368 hasRelatedWork W5204776 @default.
• W3027274368 hasRelatedWork W6243660 @default.
• W3027274368 hasRelatedWork W6564969 @default.
• W3027274368 hasRelatedWork W7159318 @default.
• W3027274368 hasRelatedWork W889026 @default.
• W3027274368 hasRelatedWork W9718870 @default.
• W3027274368 hasRelatedWork W9867636 @default.
• W3027274368 isParatext "false" @default.
• W3027274368 isRetracted "false" @default.
• W3027274368 magId "3027274368" @default.
• W3027274368 workType "article" @default.